Article
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
British journal of haematology - 1 Jul 2011
Treon Steven P, Yang Guang, Hanzis Christine, Ioakimidis Leukothea, Verselis Sigitas J, Fox Edward A, Xu Lian, Hunter Zachary R, Tseng Hsiuyi, Manning Robert J, Patterson Christopher J, Sheehy Patricia, Turnbull Barry
Abstract excerpt
The incorporation of rituximab into various regimens has improved depth of response in Waldenstrom macroglobulinaemia (WM), though the impact of achieving better responses remains to be determined. We examined response depth on progression-free survival (PFS) in 159 rituximab-naïve WM patients who received rituximab-based therapy. The median follow-up was 33·5 months, and categorical responses were as follows:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.